PMS-Methylphenidate
PMS-Methylphenidate Brand names, PMS-Methylphenidate Analogs
- 4311/B Ciba
- Calocain
- Centedein
- Centedrin
- Centedrine
- Centredin
- Concerta
- Focalin
- Focalin XR
- Methylphen
- Meridil
- Metadate
- Metadate CD
- Metadate ER
- Methyl phenidyl acetate
- Methylin
- Methylin ER
- Methylofenidan
- Methylphenidan
- Methylphenidate HCl
- Methylphenidate hydrochloride
- Methylphenidatum [Inn-Latin]
- Methylphenidylacetate hydrochloride
- Methypatch
- Metilfenidat hydrochloride
- Metilfenidato [Inn-Spanish]
- Metilfenidato [Italian]
- Phenidylate
- Plimasine
- PMS-Methylphenidate
- Riphenidate
- Ritalin
- Ritalin hydrochloride
- Ritalin LA
- Ritalin SR
- Ritalin-SR
- Ritaline
- Ritcher Works
PMS-Methylphenidate Brand Names Mixture
- No information avaliable
PMS-Methylphenidate Chemical_Formula
C14H19NO2
PMS-Methylphenidate RX_link
http://www.rxlist.com/cgi/generic/methphen.htm
PMS-Methylphenidate fda sheet
PMS-Methylphenidate msds (material safety sheet)
PMS-Methylphenidate Synthesis Reference
M. Hartmann, L. Panizzon, U.S. Pat. 2,507,631 (1950)
PMS-Methylphenidate Molecular Weight
233.306 g/mol
PMS-Methylphenidate Melting Point
224-226oC
PMS-Methylphenidate H2O Solubility
1255mg/L
PMS-Methylphenidate State
Solid
PMS-Methylphenidate LogP
3.192
PMS-Methylphenidate Dosage Forms
Tablets; Tablets (sustained release)
PMS-Methylphenidate Indication
For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.
PMS-Methylphenidate Pharmacology
Methylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine.
PMS-Methylphenidate Absorption
Readily absorbed in a biphasic manner. It reaches peak absorption at approximately two hours for the first phase and five hours for the second phase. Bioavailability is low (approximately 30%)
PMS-Methylphenidate side effects and Toxicity
Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD50=190mg/kg (orally in mice)
PMS-Methylphenidate Patient Information
PMS-Methylphenidate Organisms Affected
Humans and other mammals
